Ghoghari AM - Search Results

1

Simultaneous estimation of ZY-19489 and its active metabolite ZY-20486 in human plasma using LC-MS/MS, a novel antimalarial compound.

Ghoghari AM, Patel HV, Nayak NN, Mansuri TH, Pillai SM, Jain MR, Patel HB, Kansagra K, Resta ID, Möhrle J, Parmar DV. Ghoghari AM, et al. Bioanalysis. 2021 Dec;13(23):1761-1777. doi: 10.4155/bio-2021-0194. Epub 2021 Nov 15. Bioanalysis. 2021. PMID: 34779650

2

Quantitative determination of saroglitazar, a predominantly PPAR alpha agonist, in human plasma by a LC-MS/MS method utilizing electrospray ionization in a positive mode.

Ghoghari A, Dash R, Bhatt C, Singh K, Jha A, Patel H, Gupta R, Kansagra K, Srinivas NR. Ghoghari A, et al. Biomed Chromatogr. 2016 Dec;30(12):1900-1907. doi: 10.1002/bmc.3760. Epub 2016 Jun 23. Biomed Chromatogr. 2016. PMID: 27187607

3

Review of the bioanalytical methods for the determination of methotrexate and its metabolites in in vitro, preclinical and clinical studies: Case studies and perspectives.

Patel H, Giri P, Ghoghari A, Delvadia P, Syed M, Srinivas NR. Patel H, et al. Biomed Chromatogr. 2017 Jan;31(1). doi: 10.1002/bmc.3849. Epub 2016 Oct 17. Biomed Chromatogr. 2017. PMID: 27623319 Review.

4

Is the Inhibition of Dipeptidyl Peptidase-4 (DDP-4) Enzyme Route Dependent and/or Driven by High Peak Concentration?- Seeking Answers with ZYDPLA1, a Novel Long Acting DPP-4 Inhibitor, in a Rodent Model.

Patel H, Joharapurkar AA, Bahekar R, Patel P, Kshirsagar SG, Modi N, Ghoghari A, Patel VJ, Jain MR, Srinivas NR, Patel PR, Desai RC. Patel H, et al. Drug Res (Stuttg). 2017 Apr;67(4):223-227. doi: 10.1055/s-0042-122776. Epub 2017 Feb 3. Drug Res (Stuttg). 2017. PMID: 28158894

5

A sensitive quantitative assay for the determination of propafenone and two metabolites, 5-hydroxypropafenone and N-depropylpropafenone, in human K2EDTA plasma using LC-MS/MS with ESI operated in positive mode.

Patel H, Ghoghari A, Bhatt C, Shah S, Jha A, Desai N, Srinivas NR. Patel H, et al. Biomed Chromatogr. 2017 Oct;31(10). doi: 10.1002/bmc.3967. Epub 2017 May 7. Biomed Chromatogr. 2017. PMID: 28261841 Clinical Trial.

6

Comparative Pharmacokinetics of Cholecalciferol in Dogs from 2 Different Oral Formulations Using Corrective Measures to Overcome Interference from Endogenous Cholecalciferol.

Patel H, Patel P, Bhatt C, Ghoghari A, Patel U, Ukawalal M, Sheikh S, Ramanathan V, Srinivas NR. Patel H, et al. Drug Res (Stuttg). 2017 Jul;67(7):388-395. doi: 10.1055/s-0043-101527. Epub 2017 Apr 26. Drug Res (Stuttg). 2017. PMID: 28445901

7

One should avoid retro-orbital pharmacokinetic sample collections for intranasal dosing in rats: Illustration of spurious pharmacokinetics generated for anti-migraine drugs zolmitriptan and eletriptan.

Patel H, Patel P, Modi N, Shah S, Ghoghari A, Variya B, Laddha R, Baradia D, Dobaria N, Mehta P, Srinivas NR. Patel H, et al. Eur J Pharm Sci. 2017 Aug 30;106:87-93. doi: 10.1016/j.ejps.2017.05.044. Epub 2017 May 23. Eur J Pharm Sci. 2017. PMID: 28549679

8

Estimation of ZYKR1 in human urine and plasma utilizing LC-MS/MS positive electrospray ionization; a kappa opioid receptor (KOR) agonist.

Ghoghari A, Bhatt C, Patel K, Jha A, Patel H, Jain M, Momin T, Parmar D, Patel P. Ghoghari A, et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2021 Nov 15;1185:122982. doi: 10.1016/j.jchromb.2021.122982. Epub 2021 Oct 24. J Chromatogr B Analyt Technol Biomed Life Sci. 2021. PMID: 34731743

9

Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.

Barber BE, Fernandez M, Patel HB, Barcelo C, Woolley SD, Patel H, Llewellyn S, Abd-Rahman AN, Sharma S, Jain M, Ghoghari A, Di Resta I, Fuchs A, Deni I, Yeo T, Mok S, Fidock DA, Chalon S, Möhrle JJ, Parmar D, McCarthy JS, Kansagra K. Barber BE, et al. Lancet Infect Dis. 2022 Jun;22(6):879-890. doi: 10.1016/S1473-3099(21)00679-4. Epub 2022 Mar 2. Lancet Infect Dis. 2022. PMID: 35247321 Clinical Trial.

10

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Oral NLRP3 Inflammasome Inhibitor ZYIL1: First-in-Human Phase 1 Studies (Single Ascending Dose and Multiple Ascending Dose).

Parmar DV, Kansagra KA, Momin T, Patel HB, Jansari GA, Bhavsar J, Shah C, Patel JM, Ghoghari A, Barot A, Sharma B, Viswanathan K, Patel HV, Jain MR. Parmar DV, et al. Clin Pharmacol Drug Dev. 2023 Feb;12(2):202-211. doi: 10.1002/cpdd.1162. Epub 2022 Sep 5. Clin Pharmacol Drug Dev. 2023. PMID: 36065092 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

13 results

Search Page